Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences, Merck Pause Phase 2 HIV Trial

11/24/2021 | 05:40am EST


ę MT Newswires 2021
All news about GILEAD SCIENCES, INC.
01/21Gilead Gets FDA Approval for Remdesivir for Some Non-Hospitalized Patients
DJ
01/21FDA Approves Veklury« (Remdesivir) for the Treatment of Non-Hospitalized Patients at Hi..
BU
01/21Gilead Sciences, Inc. Announces FDA Approves Veklury« for the Treatment of Non-Hospital..
CI
01/19GLOBAL MARKETS LIVE : Bank of America, ASML, Intel, Oracle, Burberry...
01/19WALL STREET STOCK EXCHANGE : Temporary respite for the Nasdaq
01/19MARKETSCREENER’S WORLD PRESS REVIEW : January 19, 2022
01/19ANALYST RECOMMENDATIONS : Activision Blizzard, Chevron, Exxon Mobil, Gilead, Goldman Sachs..
01/19GILEAD SCIENCES : Announces Actions to Remove Counterfeit HIV Medications from U.S. Supply..
PU
01/18Gilead says counterfeit HIV drugs ended up with patients
RE
01/18Health Care Down Amid Flight From Cyclical Sectors -- Health Care Roundup
DJ
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 26 575 M - -
Net income 2021 7 179 M - -
Net Debt 2021 22 428 M - -
P/E ratio 2021 11,9x
Yield 2021 4,13%
Capitalization 85 938 M 85 938 M -
EV / Sales 2021 4,08x
EV / Sales 2022 4,23x
Nbr of Employees 13 600
Free-Float -
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 68,51 $
Average target price 75,96 $
Spread / Average Target 10,9%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-2.71%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-9.18%49 645
BIONTECH SE-42.79%35 624
BEIGENE, LTD.-7.19%25 835